文献速递生殖医学

囊胚腔液中脱氧核糖核酸检测:胚胎倍性与可存活妊娠的新预测指标

Deoxyribonucleic acid detection in blastocoelic fluid: a new predictor of embryo ploidy and viable pregnancy.
PubMed 文献 · Fertil Steril · 2018-12-05

该回顾性研究对91例患者的256枚囊胚在玻璃化冷冻前获取囊胚腔液(BF)和滋养外胚层(TE)细胞,TE细胞经a-CGH诊断倍性,BF经全基因组扩增(WGA)后行a-CGH。TE整倍体囊胚的BF扩增率显著低于非整倍体(45% vs 81%),BF与TE倍性一致率为93.6%;TE整倍体囊胚移植后,BF扩增失败组的临床妊娠率和持续妊娠率均高于BF扩增成功组。

要点

  • TE整倍体囊胚的BF WGA扩增率显著低于非整倍体囊胚(45% vs 81%)。
  • BF与对应TE细胞的倍性一致率为93.6%,BF平均非整倍体事件数高于TE细胞(2.0 vs 1.4)。
  • TE整倍体囊胚移植后,BF扩增失败组临床妊娠率和持续妊娠率均高于扩增成功组。

核心结论

  • WGA检测到的BF中DNA存在与TE细胞活检定义的囊胚倍性状态及TE整倍体囊胚的种植潜能相关。
  • 作者认为这些发现可能对选择最具活力的胚胎移植有临床意义,因为BF行WGA后,优先选择BF扩增失败的TE整倍体囊胚。
  • 同样,BF扩增失败可作为优先移植胚胎的额外选择标准,即使在常规IVF周期中,囊胚在BF抽吸后玻璃化冷冻。

研究设计与样本

  • 回顾性研究,在体外受精单位进行,纳入2015年1月至2017年12月期间对TE细胞行胚胎植入前非整倍体遗传学检测的91例患者。
  • 共256枚囊胚在玻璃化冷冻前获取BF和TE细胞,所有囊胚的TE细胞经阵列比较基因组杂交(a-CGH)诊断;BF的DNA扩增和a-CGH在TE活检和胚胎移植后稍晚时间进行。
  • 胚胎移植时仅行单囊胚移植。

主要发现

  • TE整倍体囊胚的BF WGA扩增率为45%(n=32),非整倍体囊胚为81%(n=150),前者显著低于后者,共182份BF DNA扩增成功。
  • 对182份BF行a-CGH,其中172份获得信息性结果;与对应TE细胞结果比较,倍性一致率为93.6%,BF平均非整倍体事件数高于TE细胞(2.0 vs 1.4)。
  • 移植53枚TE整倍体囊胚后,BF扩增失败组临床妊娠率为77%,BF扩增成功组为37%;持续妊娠率分别为68% vs 31.5%。

临床怎么用

  • 作者认为BF行WGA后,优先选择BF扩增失败的TE整倍体囊胚移植。
  • 作者认为BF扩增失败可作为优先移植胚胎的额外选择标准,即使在常规IVF周期中囊胚于BF抽吸后玻璃化冷冻。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate blastocysts, defined as euploid and aneuploid by trophectoderm (TE) cell analysis, for the presence of DNA in the blastocoelic fluid (BF) detected by whole-genomic amplification (WGA); and to correlate the presence of DNA in BF with the clinical outcome after the transfer of TE-euploid blastocysts. DESIGN: Retrospective study. SETTING: In vitro fertilization unit. PATIENT(S): This study included 91 patients performing preimplantation genetic testing for aneuploidy on TE cells from January 2015 to December 2017. In the case of ET, only single blastocyst transfers were performed. INTERVENTION(S): Blastocoelic fluids and TE cells were retrieved from 256 blastocysts before vitrification. All blastocysts were diagnosed by array-comparative genomic hybridization (a-CGH) on TE cells. Amplification and a-CGH of DNA from BFs was performed at a later time after TE biopsy and ET. MAIN OUTCOME MEASURE(S): Whole-genomic amplification of BFs, evaluation of the chromosome condition in BFs and TE cells, and correlation of BF results with the clinical outcome of TE-euploid transferred blastocysts. RESULT(S): The incidence of amplification after WGA was significantly lower in BFs from TE-euploid blastocysts (n = 32, 45%) when compared with the aneuploid ones (n = 150, 81%), resulting in 182 BFs with successful DNA amplification. When submitted to a-CGH, informative results were obtained from 172 BFs. Comparison of these results with those from the corresponding TE cells gave a ploidy concordance of 93.6% and a mean number of aneuploid events per sample that was higher in BFs than in TE cells (2.0 vs. 1.4, respectively). After the transfer of 53 TE-euploid blastocysts, the clinical pregnancy rate was 77% in the group with BF-failed amplification, and 37% after BF-successful amplification. The same trend was found for the ongoing pregnancy rate (68% vs. 31.5%, respectively). CONCLUSION(S): The presence of DNA in BFs detected by WGA is correlated with the blastocyst ploidy condition defined by TE cell biopsy and with the implantation potential of TE-euploid blastocysts. These findings could have a clinical implication for the selection of the most viable embryo for transfer because, after submitting BFs to WGA, priority would be given to TE-euploid blastocysts with BF-failed amplification. Similarly, BF-failed amplification could be an additional selection criterion to prioritize embryos for transfer even in conventional IVF cycles with blastocysts that were vitrified after BF aspiration.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Magli MC, Albanese C, Crippa A, et al. Deoxyribonucleic acid detection in blastocoelic fluid: a new predictor of embryo ploidy and viable pregnancy. Fertil Steril. 2018. PMID: 30528055. doi:10.1016/j.fertnstert.2018.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。